Journal Article
. 2007 Nov;8(12).
doi: 10.1016/S1470-2045(07)70346-7.

Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)

Jolien M Bueno-de-Mesquita 1 Wim H van Harten 2 Valesca P Retel 2 Laura J van 't Veer 3 Frits Sam van Dam 2 Kim Karsenberg 2 Kirsten Fl Douma 2 Harm van Tinteren 4 Johannes L Peterse 1 Jelle Wesseling 1 Tin S Wu 1 Douwe Atsma 1 Emiel Jt Rutgers 5 Guido Brink 6 Arno N Floore 6 Annuska M Glas 6 Rudi Mh Roumen 7 Frank E Bellot 8 Cees van Krimpen 9 Sjoerd Rodenhuis 10 Marc J van de Vijver 11 Sabine C Linn 12 
  • PMID: 18042430
  •     73 citations


Background: A microarray-based 70-gene prognosis signature might improve the selection of patients with node-negative breast cancer for adjuvant systemic treatment. The main aims of this MicroarRAy PrognoSTics in Breast CancER (RASTER) study were to assess prospectively the feasibility of implementation of the 70-gene prognosis signature in community-based settings and its effect on adjuvant systemic treatment decisions when considered with treatment advice formulated from the Dutch Institute for Healthcare Improvement (CBO) and other guidelines.

Methods: Between January, 2004 and December, 2006, 812 women aged under 61 years with primary breast carcinoma (clinical T1-4N0M0) were enrolled. Fresh tumour samples were collected in 16 hospitals in the Netherlands within 1 h after surgery. Clinicopathological factors were collected and microarray analysis was done with a custom-designed array chip that assessed the mRNA expression index of the 70 genes previously identified for the prognostic signature. Patients with a "good" signature were deemed to have a good prognosis and, therefore, could be spared adjuvant systemic treatment with its associated adverse effects, whereas patients with a "poor" signature were judged to have a poor prognosis and should be considered for adjuvant systemic treatment. Concordance between risk predicted by the prognosis signature and risk predicted by commonly used clinicopathological guidelines (ie, St Gallen guidelines, Nottingham Prognostic Index, and Adjuvant! Online) was assessed.

Findings: Of 585 eligible patients, 158 patients were excluded because of sampling failure (n=128) and incorrect procedure (n=30). Prognosis signatures were assessed in 427 patients. The 70-gene prognosis signature identified 219 (51%) patients with good prognosis and 208 (49%) patients with poor prognosis. The Dutch CBO guidelines identified 184 patients (43%) with poor prognosis, which was discordant with those findings obtained with the prognosis signature in 128 (30%) patients. Oncologists recommended adjuvant treatment in 203 (48%) patients based on Dutch CBO guidelines, in 265 (62%) patients if the guidelines were used with the prognosis signature, and in 259 (61%) patients if Dutch CBO guidelines, prognosis signature, and patients' preferences for treatment were all taken into account. Adjuvant! Online guidelines identified more patients with poor prognosis than did the signature alone (294 [69%]), and discordance with the signature occurred in 160 (37%) patients. St Gallen guidelines identified 353 (83%) patients with poor prognosis with the signature and discordance in 168 (39%) patients. Nottingham Prognostic Index recorded 179 (42%) patients with poor prognosis with the signature and discordance in 117 (27%) patients.

Interpretation: Use of the prognosis signature is feasible in Dutch community hospitals. Adjuvant systemic treatment was advised less often when the more restrictive Dutch CBO guidelines were used compared with that finally given after use of the prognosis signature. For the other guidelines assessed, less adjuvant chemotherapy would be given when the data based on prognosis signature alone are used, which might spare patients from adverse effects and confirms previous findings. Future studies should assess whether use of the prognosis signature could improve survival or equal survival while avoiding unnecessary adjuvant systemic treatment without affecting patients' survival, and further assess the factors that physicians use to recommend adjuvant systemic treatment.

Transcriptomic biomarkers for individual risk assessment in new-onset heart failure.
Bettina Heidecker, Edward K Kasper, +6 authors, Joshua M Hare.
Circulation, 2008 Jul 02; 118(3). PMID: 18591436    Free PMC article.
Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data.
Jiangang Liu, Andrew Campen, +6 authors, Shuyu Li.
BMC Med Genomics, 2008 Sep 13; 1. PMID: 18786252    Free PMC article.
Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice.
M A Pantaleo, A Astolfi, +8 authors, G Biasco.
Br J Cancer, 2008 Oct 02; 99(10). PMID: 18827815    Free PMC article.
[Genome-wide expression profiling as a clinical tool: are we there yet?].
F C Geyer, T Decker, J S Reis-Filho.
Pathologe, 2009 Feb 17; 30(2). PMID: 19219435
Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics.
P D Williams, J K Lee, D Theodorescu.
Curr Oncol, 2009 Feb 21; 16(1). PMID: 19229372    Free PMC article.
Genetic characterization of breast cancer and implications for clinical management.
Felipe C Geyer, Maria A Lopez-Garcia, Maryou B Lambros, Jorge S Reis-Filho.
J Cell Mol Med, 2009 Sep 17; 13(10). PMID: 19754664    Free PMC article.
Comparability of microarray data between amplified and non amplified RNA in colorectal carcinoma.
Roland S Croner, Berthold Lausen, +8 authors, Wolfgang M Brueckl.
J Biomed Biotechnol, 2009 Oct 15; 2009. PMID: 19826639    Free PMC article.
Genomic markers for decision making: what is preventing us from using markers?
Vicky M Coyle, Patrick G Johnston.
Nat Rev Clin Oncol, 2009 Dec 17; 7(2). PMID: 20010899
Multidisciplinary approach of early breast cancer: the biology applied to radiation oncology.
Céline Bourgier, Mahmut Ozsahin, David Azria.
Radiat Oncol, 2010 Jan 16; 5. PMID: 20074364    Free PMC article.
Cardiovascular genetic medicine: genomic assessment of prognosis and diagnosis in patients with cardiomyopathy and heart failure.
Bettina Heidecker, Joshua M Hare.
J Cardiovasc Transl Res, 2008 Sep 01; 1(3). PMID: 20559924    Free PMC article.
Meta-analysis of cancer gene expression signatures reveals new cancer genes, SAGE tags and tumor associated regions of co-regulation.
Ersen Kavak, Mustafa Unlü, Monica Nistér, Ahmet Koman.
Nucleic Acids Res, 2010 Jul 14; 38(20). PMID: 20621981    Free PMC article.
Gene-expression profiling in breast cancer: bespoke cancer therapy or more fiction than science?
M Barry, M R Kell.
Ir J Med Sci, 2010 Sep 03; 179(4). PMID: 20809382
Breast cancer assessment tools and optimizing adjuvant therapy.
Catherine Oakman, Libero Santarpia, Angelo Di Leo.
Nat Rev Clin Oncol, 2010 Oct 27; 7(12). PMID: 20975745
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature.
M Knauer, F Cardoso, +4 authors, L J van 't Veer.
Br J Cancer, 2010 Nov 18; 103(12). PMID: 21081926    Free PMC article.
Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?
Takayuki Iwamoto, Lajos Pusztai.
Genome Med, 2010 Nov 26; 2(11). PMID: 21092148    Free PMC article.
[Long-term survival of personalized surgical treatment of locally advanced non-small cell lung cancer based on molecular staging].
Qinghua Zhou, Yingkang Shi, +14 authors, Zhu Wu.
Zhongguo Fei Ai Za Zhi, 2011 Feb 24; 14(2). PMID: 21342639    Free PMC article.
Transcriptomic biomarkers for the accurate diagnosis of myocarditis.
Bettina Heidecker, Michelle M Kittleson, +7 authors, Joshua M Hare.
Circulation, 2011 Mar 09; 123(11). PMID: 21382894    Free PMC article.
Relationship of extreme chromosomal instability with long-term survival in a retrospective analysis of primary breast cancer.
Rebecca Roylance, David Endesfelder, +12 authors, Charles Swanton.
Cancer Epidemiol Biomarkers Prev, 2011 Jul 26; 20(10). PMID: 21784954    Free PMC article.
Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.
Pierre-Emmanuel Colombo, Fernanda Milanezi, Britta Weigelt, Jorge S Reis-Filho.
Breast Cancer Res, 2011 Jul 27; 13(3). PMID: 21787441    Free PMC article.
The 70-gene prognostic signature for korean breast cancer patients.
Kuk Young Na, Ku Sang Kim, +7 authors, Yong Sik Jung.
J Breast Cancer, 2011 Aug 19; 14(1). PMID: 21847392    Free PMC article.
Challenges translating breast cancer gene signatures into the clinic.
Britta Weigelt, Lajos Pusztai, Alan Ashworth, Jorge S Reis-Filho.
Nat Rev Clin Oncol, 2011 Sep 01; 9(1). PMID: 21878891
Impact of mammographic screening on the detection of good and poor prognosis breast cancers.
Laura J Esserman, Yiwey Shieh, +8 authors, Laura J van 't Veer.
Breast Cancer Res Treat, 2011 Sep 06; 130(3). PMID: 21892702    Free PMC article.
Gene expression profiling: changing face of breast cancer classification and management.
Robert Wesolowski, Bhuvaneswari Ramaswamy.
Gene Expr, 2012 Jan 25; 15(3). PMID: 22268293    Free PMC article.
Individualization of cancer treatment from radiotherapy perspective.
Ala Yaromina, Mechthild Krause, Michael Baumann.
Mol Oncol, 2012 Mar 03; 6(2). PMID: 22381063    Free PMC article.
The molecular basis of chemoradiosensitivity in rectal cancer: implications for personalized therapies.
Marian Grade, Hendrik A Wolff, Jochen Gaedcke, B Michael Ghadimi.
Langenbecks Arch Surg, 2012 Mar 03; 397(4). PMID: 22382702    Free PMC article.
Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma.
Fabien Reyal, Marc A Bollet, +9 authors, Xavier Sastre-Garau.
PLoS One, 2012 Apr 25; 7(4). PMID: 22529987    Free PMC article.
The 70-Gene Signature as Prognostic Factor for Elderly Women with Hormone Receptor-Positive, HER2-Negative Breast Cancer.
Steffi Hartmann, Bernd Gerber, +2 authors, Toralf Reimer.
Breast Care (Basel), 2012 May 04; 7(1). PMID: 22553468    Free PMC article.
Proteomic studies in breast cancer (Review).
Xian-Ju Qin, Bruce X Ling.
Oncol Lett, 2012 Jun 29; 3(4). PMID: 22740985    Free PMC article.
The non-crosslinking fixative RCL2®-CS100 is compatible with both pathology diagnosis and molecular analyses.
Florence Boissière-Michot, Amélie Denouël, +5 authors, Frédéric Bibeau.
Pathol Oncol Res, 2012 Aug 16; 19(1). PMID: 22893391
Scenario drafting to anticipate future developments in technology assessment.
Valesca P Retèl, Manuela A Joore, +2 authors, Wim H van Harten.
BMC Res Notes, 2012 Aug 17; 5. PMID: 22894140    Free PMC article.
Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients.
Michael R Mallmann, Andrea Staratschek-Jox, +5 authors, Joachim L Schultze.
EPMA J, 2010 Sep 01; 1(3). PMID: 23199086    Free PMC article.
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.
C A Drukker, J M Bueno-de-Mesquita, +10 authors, S C Linn.
Int J Cancer, 2013 Feb 02; 133(4). PMID: 23371464    Free PMC article.
A data similarity-based strategy for meta-analysis of transcriptional profiles in cancer.
Qingchao Qiu, Pengcheng Lu, +6 authors, Yajun Yi.
PLoS One, 2013 Feb 06; 8(1). PMID: 23383020    Free PMC article.
Computational purification of individual tumor gene expression profiles leads to significant improvements in prognostic prediction.
Gerald Quon, Syed Haider, +3 authors, Quaid Morris.
Genome Med, 2013 Mar 30; 5(3). PMID: 23537167    Free PMC article.
Association between genomic recurrence risk and well-being among breast cancer patients.
Valesca P Retèl, Catharina G M Groothuis-Oudshoorn, +3 authors, Wim H van Harten.
BMC Cancer, 2013 Jun 20; 13. PMID: 23777535    Free PMC article.
Testing personalized medicine: patient and physician expectations of next-generation genomic sequencing in late-stage cancer care.
Fiona A Miller, Robin Z Hayeems, +10 authors, Lillian L Siu.
Eur J Hum Genet, 2013 Jul 19; 22(3). PMID: 23860039    Free PMC article.
Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer.
Otto Metzger-Filho, Aurélie Catteau, +21 authors, Christos Sotiriou.
PLoS One, 2013 Aug 31; 8(8). PMID: 23990869    Free PMC article.
Molecular profiling for breast cancer: a comprehensive review.
Muaiad Kittaneh, Alberto J Montero, Stefan Glück.
Biomark Cancer, 2013 Nov 20; 5. PMID: 24250234    Free PMC article.
MammaPrint Feasibility in a Large Tertiary Urban Medical Center: An Initial Experience.
C Francisco Espinel, Shaughn Keating, +4 authors, Sheldon Feldman.
Scientifica (Cairo), 2012 Jan 01; 2012. PMID: 24278759    Free PMC article.
Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score.
Sung Gwe Ahn, Hak Min Lee, +5 authors, In-Sun Chu.
Int J Mol Sci, 2013 Dec 07; 14(12). PMID: 24304542    Free PMC article.
Network Based Prediction Model for Genomics Data Analysis.
Ying Huang, Pei Wang.
Stat Biosci, 2012 Apr 01; 4(1). PMID: 24348880    Free PMC article.
Breast Cancer Biomarkers: Utility in Clinical Practice.
Fanny Le Du, Naoto T Ueno, Ana M Gonzalez-Angulo.
Curr Breast Cancer Rep, 2014 Jan 15; 5(4). PMID: 24416469    Free PMC article.
Molecular tests as prognostic factors in breast cancer.
Marc J van de Vijver.
Virchows Arch, 2014 Feb 04; 464(3). PMID: 24487789
Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms.
C A Drukker, M V Nijenhuis, +10 authors, S C Linn.
Breast Cancer Res Treat, 2014 Apr 25; 145(3). PMID: 24760482    Free PMC article.
Modern Risk Assessment for Individualizing Treatment Concepts in Early-stage Breast Cancer.
Alex Farr, Rachel Wuerstlein, +2 authors, Nadia Harbeck.
Rev Obstet Gynecol, 2013 Jan 01; 6(3-4). PMID: 24920978    Free PMC article.
Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.
Laura Zanotti, Alberto Bottini, +2 authors, Maria Rosa Cappelletti.
Tumour Biol, 2014 Jul 23; 35(9). PMID: 25048969
Clinical utility of gene-expression profiling in women with early breast cancer: an overview of systematic reviews.
Michael Marrone, Alison Stewart, W David Dotson.
Genet Med, 2014 Dec 05; 17(7). PMID: 25474343    Free PMC article.
Application of a 70-Gene Expression Profile to Japanese Breast Cancer Patients.
Hideo Shimizu, Yoshiya Horimoto, +14 authors, Mitsue Saito.
Breast Care (Basel), 2015 Jul 22; 10(2). PMID: 26195940    Free PMC article.
Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential.
Claudia Cava, Gloria Bertoli, Isabella Castiglioni.
BMC Syst Biol, 2015 Sep 24; 9. PMID: 26391647    Free PMC article.
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.
Joseph A Sparano, Robert J Gray, +28 authors, George W Sledge.
N Engl J Med, 2015 Sep 29; 373(21). PMID: 26412349    Free PMC article.
Highly Cited.
Scenario drafting for early technology assessment of next generation sequencing in clinical oncology.
S E P Joosten, V P Retèl, +2 authors, W H van Harten.
BMC Cancer, 2016 Feb 08; 16. PMID: 26851938    Free PMC article.
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectives.
Meagan B Myers.
Pharmgenomics Pers Med, 2016 Feb 10; 9. PMID: 26858530    Free PMC article.
Equivalence of MammaPrint array types in clinical trials and diagnostics.
Inès Beumer, Anke Witteveen, +11 authors, Annuska Glas.
Breast Cancer Res Treat, 2016 Mar 24; 156(2). PMID: 27002507    Free PMC article.
Assessing the clinical utility of genomic expression data across human cancers.
Xinsen Xu, Lei Huang, +3 authors, Chang Liu.
Oncotarget, 2016 Jun 21; 7(29). PMID: 27322207    Free PMC article.
From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.
Jan C Brase, Ralf Kronenwett, +2 authors, Marcus Schmidt.
Microarrays (Basel), 2013 Jan 01; 2(3). PMID: 27605191    Free PMC article.
Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.
Vida Pourteimoor, Samira Mohammadi-Yeganeh, Mahdi Paryan.
Tumour Biol, 2016 Sep 22; 37(11). PMID: 27651157
Involvement of microRNAs in HER2 signaling and trastuzumab treatment.
Ling Mao, Ai-Jun Sun, Jian-Zhong Wu, Jin-Hai Tang.
Tumour Biol, 2016 Oct 14;. PMID: 27734339
Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women.
Sarah M Bernhardt, Pallave Dasari, +3 authors, Wendy V Ingman.
Front Oncol, 2016 Nov 30; 6. PMID: 27896218    Free PMC article.
Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation.
W H van Harten, V P Retèl.
Ecancermedicalscience, 2016 Dec 03; 10. PMID: 27899956    Free PMC article.
Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer.
Inès J Beumer, Marion Persoon, +9 authors, Annuska M Glas.
Biomark Insights, 2016 Dec 17; 11. PMID: 27980389    Free PMC article.
Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.
David M Hyams, Eric Schuur, +7 authors, Aníbal Nuñez De Pierro.
J Surg Oncol, 2017 Feb 18; 115(6). PMID: 28211064    Free PMC article.
A breast cancer gene signature for indolent disease.
Leonie J M J Delahaye, Caroline A Drukker, +8 authors, Annuska M Glas.
Breast Cancer Res Treat, 2017 Apr 30; 164(2). PMID: 28451965    Free PMC article.
Statistical Contributions to Bioinformatics: Design, Modeling, Structure Learning, and Integration.
Jeffrey S Morris, Veerabhadran Baladandayuthapani.
Stat Modelling, 2017 Nov 14; 17(4-5). PMID: 29129969    Free PMC article.
Elevation of MAP17 enhances the malignant behavior of cells via the Akt/mTOR pathway in hepatocellular carcinoma.
Xinhuang Chen, Yan Liao, +5 authors, Zhaoquan Huang.
Oncotarget, 2017 Dec 02; 8(54). PMID: 29190940    Free PMC article.
Enrichment of high-grade tumors in breast cancer gene expression studies.
M van Seijen, A L Mooyaart, +7 authors, E H Lips.
Breast Cancer Res Treat, 2017 Dec 20; 168(2). PMID: 29256013    Free PMC article.
Editorial: How Reproductive History Influences Our Breast Cancer Risk.
Robin L Anderson, Wendy V Ingman, Kara L Britt.
Front Oncol, 2018 Jan 30; 7. PMID: 29376022    Free PMC article.
Quantitative or qualitative transcriptional diagnostic signatures? A case study for colorectal cancer.
Qingzhou Guan, Haidan Yan, +10 authors, Zheng Guo.
BMC Genomics, 2018 Jan 31; 19(1). PMID: 29378509    Free PMC article.
MammaPrint guides treatment decisions in breast Cancer: results of the IMPACt trial.
Hatem Soliman, Varsha Shah, +11 authors, William Audeh.
BMC Cancer, 2020 Feb 02; 20(1). PMID: 32005181    Free PMC article.
Performance Characteristics of the BluePrint® Breast Cancer Diagnostic Test.
Lorenza Mittempergher, Leonie Jmj Delahaye, +7 authors, Annuska M Glas. Electronic address:
Transl Oncol, 2020 Mar 26; 13(4). PMID: 32208353    Free PMC article.
Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review.
David Krug, René Baumann, +12 authors, Rolf Sauer.
Breast Care (Basel), 2020 May 14; 15(2). PMID: 32398980    Free PMC article.
An interobserver reproducibility analysis of size-set semiautomatic counting for Ki67 assessment in breast cancer.
Yi-Xing Wang, Yuan-Yuan Wang, +9 authors, Ju-Lun Yang.
Breast, 2020 Jan 09; 49. PMID: 31911370    Free PMC article.
Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences.
Ana Tablante Nunes, Deborah E Collyar, Lyndsay N Harris.
JNCI Cancer Spectr, 2017 Dec 11; 1(1). PMID: 31360834    Free PMC article.
A Five-Gene-Pair-Based Prognostic Signature for Predicting the Relapse Risk of Early Stage ER+ Breast Cancer.
Na Li, Hao Cai, +7 authors, Zheng Guo.
Front Genet, 2020 Nov 17; 11. PMID: 33193655    Free PMC article.